Aptus Pharma Ltd Intrinsic Value
APPL · Healthcare · Current price ₹251.2
Is Aptus Pharma Ltd undervalued?
DocStoX estimates the fair value of Aptus Pharma Ltd at ₹40 per share, versus the current market price of ₹251. That puts the stock about -84.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is medium.
How this fair value is calculated
This estimate blends 2 independent methods: Residual income (₹43), Graham floor (₹27). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹27 (bear) to ₹40 (base) to ₹45 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹251 versus an intrinsic value of ₹40, Aptus Pharma Ltd currently offers -84.3% of negative margin (i.e. a premium).
More on Aptus Pharma Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.